Pacira Delivers Q2 Growth, Completes iovera° Sale, and Refreshes Outlook
PCRX sits 47% above its 52-week low of $18.8 on elevated volume (2.2× avg).
Summary
Pacira BioSciences posted Q2 2026 revenue of $192.4 million, a 6% year-over-year increase, and closed the sale of its iovera° business to Zimmer Biomet for up to $140 million. A major reimbursement win for EXPAREL with UnitedHealthcare was also announced, and full-year guidance was updated to account for the divestiture.
Key Events · Earnings and Guidance · PCRX
-
Q2 Revenue Up 6% to $192.4M
Driven by EXPAREL sales of $147.8 million (+3%) and ZILRETTA sales of $32.6 million (+4%), total revenue rose 6% year-over-year to $192.4 million. The bottom line swung to a GAAP net income of $4.7 million, or $0.12 per share, from a net loss of $4.8 million a year ago.
-
iovera° Divestiture Closed for Up to $140M
The sale of the iovera° business to Zimmer Biomet closed on July 31, 2026. After adjustments, Pacira received $73.6 million in cash and could earn up to an additional $70 million in revenue-based milestones through 2031. The transaction sheds a non-core asset while bolstering the balance sheet.
-
UnitedHealthcare to Reimburse EXPAREL Separately
UnitedHealthcare, the largest U.S. health insurer with approximately 40 million covered lives, will now provide separate reimbursement for EXPAREL in outpatient settings. This decision broadens patient access and could fuel higher adoption and revenue growth.
-
Gene Therapy Pipeline Progresses
PCRX-201, a gene therapy for knee osteoarthritis, advanced to Part B of the Phase 2 ASCEND study. Topline data from Part A are expected by the end of 2026. Additionally, a Phase 1 study has been accepted for publication in a leading rheumatology journal.
Analysis · PCRX · Life Sciences
A 6% revenue gain and a swing to GAAP profitability highlight Pacira's solid second quarter, but the strategic divestiture of iovera° to Zimmer Biomet for up to $140 million takes center stage. By sharpening its focus on the core non-opioid pain franchise, the deal generated $73.6 million in immediate cash and fortifies the balance sheet. In a significant commercial development, UnitedHealthcare will now separately reimburse EXPAREL, a move likely to accelerate adoption. Meanwhile, the gene therapy pipeline advanced with Phase 2 enrollment underway. The guidance revision reflects only the iovera° exit, not operational softness. Coming on the heels of a proxy contest, these results and strategic steps lend credibility to management's '5x30' plan and may strengthen investor conviction.
At the time of this filing, PCRX was trading at $27.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $18.80 to $27.66. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.